Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis
- PMID: 26773756
- DOI: 10.1111/bjh.13911
Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis
Abstract
The role of the fibrinolytic system in the development of venous thrombosis (VT) is unclear. We studied the risk of first and recurrent VT associated with reduced fibrinolysis, as measured by clot lysis time (CLT). We also studied the relationship between CLT and thrombin generation to determine if any relationship between CLT and VT was affected by thrombin generation. Analyses were performed in the Thrombophilia Hypercoagulability Environmental risk for Venous Thromboembolism Study, a two-centre population-based case-control study, including 579 patients and 338 controls, with patients followed from the event to determine incidence of recurrent VT. Hypofibrinolysis was associated with a 1·8-fold increased risk of a first VT [95% confidence interval (CI) 1·2-2·7]. Adjustment for sex, age, study location and Endogenous Thrombin Potential (ETP) did not change the result. The risk of VT was 2·9-fold increased when the 90th percentiles of prolonged CLT and high ETP were combined, with the highest risk for unprovoked first events (Odds Ratio = 4·2, 95% CI 1·3-13·5). In the follow-up study the Hazard Ratio for a recurrent VT associated with hypofibrinolysis was 1·5 (95% CI 0·9-2·6). A weak dose response effect was observed in relation to prolongation of CLT and recurrent VT. Although hypofibrinolysis constitutes a risk factor for a first VT, an association with recurrence is, at best, weak.
Keywords: fibrinolysis; risk factors; thrombin; venous thrombosis.
© 2016 John Wiley & Sons Ltd.
Similar articles
-
Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis.PLoS Med. 2008 May 6;5(5):e97. doi: 10.1371/journal.pmed.0050097. PLoS Med. 2008. PMID: 18462012 Free PMC article.
-
Prothrombotic fibrin clot properties associated with increased endogenous thrombin potential and soluble P-selectin predict occult cancer after unprovoked venous thromboembolism.J Thromb Haemost. 2019 Nov;17(11):1912-1922. doi: 10.1111/jth.14579. Epub 2019 Aug 8. J Thromb Haemost. 2019. PMID: 31323706
-
Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence.Br J Haematol. 2007 Sep;138(6):769-74. doi: 10.1111/j.1365-2141.2007.06738.x. Br J Haematol. 2007. PMID: 17760809
-
Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.Semin Thromb Hemost. 2017 Mar;43(2):178-184. doi: 10.1055/s-0036-1585081. Epub 2016 Jul 29. Semin Thromb Hemost. 2017. PMID: 27472427 Review.
-
Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment.Eur J Clin Invest. 2021 Apr;51(4):e13471. doi: 10.1111/eci.13471. Epub 2020 Dec 16. Eur J Clin Invest. 2021. PMID: 33296082 Review.
Cited by
-
Onset of Coagulation Function Recovery Is Delayed in Severely Injured Trauma Patients with Venous Thromboembolism.J Am Coll Surg. 2017 Jul;225(1):42-51. doi: 10.1016/j.jamcollsurg.2017.03.001. Epub 2017 Mar 16. J Am Coll Surg. 2017. PMID: 28315812 Free PMC article. Clinical Trial.
-
Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.Int J Mol Sci. 2021 Feb 2;22(3):1472. doi: 10.3390/ijms22031472. Int J Mol Sci. 2021. PMID: 33540604 Free PMC article. Review.
-
Association of periodontitis with cardiometabolic and haemostatic parameters.Clin Oral Investig. 2024 Aug 30;28(9):506. doi: 10.1007/s00784-024-05893-y. Clin Oral Investig. 2024. PMID: 39212739 Free PMC article.
-
Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial.Br J Haematol. 2020 Sep;190(6):916-922. doi: 10.1111/bjh.16648. Epub 2020 Apr 16. Br J Haematol. 2020. PMID: 32301122 Free PMC article. Clinical Trial.
-
Research into New Molecular Mechanisms in Thrombotic Diseases Paves the Way for Innovative Therapeutic Approaches.Int J Mol Sci. 2024 Feb 21;25(5):2523. doi: 10.3390/ijms25052523. Int J Mol Sci. 2024. PMID: 38473772 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical